Arthritis of Temporomandibular JointARTEMISNCT03627429
Treatment of Temporomandibular Joint Osteoarthritis by Viscosupplement. Satisfaction Predictive Factors
An observational study of Arthritis of Temporomandibular Joint and Temporomandibular Arthritis, run by Labrha at 1 site in France.
Trial summary
The arthritis of temporomandibular joint is the most frequent degenerative disease of the jaw joint. Several clinical studies recommend the recourse to the viscosupplement because of its efficiency in the long term. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Arthritis of Temporomandibular Joint, Temporomandibular Arthritis
- How many people
- 36 participants
- Where
- 1 siteFrance
- Study dates
- 30 Apr 2016to Jun 2018
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Forty patients having a hallux rigidus asserted radiologically and justifying according to the opinion of the rhumalologist or the surgeon a viscosupplementation. The study is realized in the conditions of daily practice, it modifies not at all the therapeutic care of the patient
Who may be able to join
- Patients of both genders, of all ages
- Hallux rigidus confirmed by radiography including frontal and side radiographies performed during the last 12 months
- Patients requiring a viscosupplement based on the opinion of the investigator
- Patients were able to read and understand the information sheet, to give their enlighted consent and to respect follow up consultations
Who cannot join
- Patient with hypersensitivity to hyaluronic acid or mannitol
- Patient with a contraindication to the injection procedure : infected skin lesions on or close to an injection site, infectious disease ongoing
- Patient who received a viscosuplement during the last 6 months
- Patient who received an intra-articular injection of corticoids in the target articulation during the last 3 month before the inclusion
- Patient not talking french
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Treatment of Temporomandibular Joint Osteoarthritis by an Intra-articular Injection of Hyaluronic Acid. Study of Patient Satisfaction Predictive Factors, 6 Months After a Single Injection of Hyaluronic Acid.
The arthritis of temporomandibular joint is the most frequent degenerative disease of the jaw joint. Several clinical studies recommend the recourse to the viscosupplement because of its efficiency in the long term.
The present research has for objective to find clinical factors predictive of success or failure of viscosupplementation in ATM such as clinical severity before injection, the presence of a limited mouth opening or lenght of symptoms.
Read more
It is an open observational monocentrical prospective study. The recruitment is competitive and the study will be ended when 44 patients will have been included by taking into account a risk of trial exits or of lost of sight of 10 %.The main criterion is the influence of the radiological stage on the answer to the treatment.
Duration of inclusion 6 months. Duration of follow-up 6 months. Total duration of the study 12 months.
Read the detailed description
Forty patients presenting an ATM asserted by radiography and justifying a viscosupplement, without other selection criterion than the opinion of the investigator concerning the legitimacy of a viscosupplement and the agreement of the patient participating in the study.
The data collected during the consultations at J0, J90 and J180 will be inputed by the investigator in the paper version of the CRF.
The informations collected during the initial consultation (J0) are: demographic (sex, age, weight, size), pathological (history of the disease, target side, previous treatments, evaluation of pain at chewing and palpation (scale of Likert : 11 points), the inter-incisive distance during the maximal opening.
The informations collected during J90 and the final consultation (J180) are: the evaluation of pain at chewing and palpation (scale of Likert 11 points), the perception by the patient of the efficiency of the treatment (scale of Likert 4 points), patient satisfaction score, variation of its consumption of analgesic or of AINS (scale of Likert 5 points).
A descriptive analysis will be performed to characterize the demographic data, the history of the disease and its treatments, as well as the clinical and radiological data of the patients in the date of the inclusion.
The response to the treatment (Yes/No) will be estimated by 3 complementary terms, and for each one of them, the predictive response factors will be studied. Each patient will be classified in one of the treatment response categories based on the patients efficacy assessment, the pain decrease of at least 3 points or of at least 50% on the Likert scale, the satisfaction level of the patient.
The coefficients of the multivariate models (ANCOVA and mixed model) will be considered as significant if their p-value is inferior to the threshold of 5%.
- Keywords
- temporomandibular arthritis, temporomandibular joint, rheumatoid arthritis, viscosupplementation, hyaluronic acid
- Medical subject headings
- Arthritis, Rheumatoid
What is being measured
The primary outcome is the main question the study is designed to answer.
clinical factors associated with the treatment response in temporomandibular joint arthritis
Assessment of since how long the patient has these pains (in months)
Measured: 6 months
Secondary outcomes (2)
clinical factors associated with the treatment response in temporomandibular joint arthritis
Assessment of the pain intensity on a 11-point Likert scale
Measured: 6 months
clinical factors associated with the treatment response in temporomandibular joint arthritis
Assessment of the mouth opening (in mm)
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Aug 2018
- Study start30 Apr 2016
- Primary completionApr 2018
- Study completionJun 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Arthritis of Temporomandibular JointStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 36 participants (actual)
Sponsor and investigators
- Lead sponsor
- Labrha
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- DOMINIQUE BARON, MD, Principal investigator, CH LANNION
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03627429
- Sponsor's protocol ID
- 2016-A00177-44
- Acronym
- ARTEMIS
- Status last verified
- Aug 2018
- First submitted
- 5 Mar 2018
- Last updated
- 13 Aug 2018
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Treatment of Temporomandibular Joint Osteoarthritis by an Intra-articular Injection of Hyaluronic Acid. Study of Patient Satisfaction Predictive Factors, 6 Months After a Single Injection of Hyaluronic Acid.
- ClinicalTrials.gov ID
- NCT03627429
- Acronym / sponsor ID
- ARTEMIS / 2016-A00177-44
- Keywords
- temporomandibular arthritis, temporomandibular joint, rheumatoid arthritis, viscosupplementation, hyaluronic acid
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 36 participants (actual)
- Lead sponsor
- LabrhaIndustry (pharma, biotech, devices)
- Study start
- 30 Apr 2016
- Primary completion
- Apr 2018 (actual)
- Study completion
- Jun 2018 (actual)
- First posted
- 13 Aug 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The arthritis of temporomandibular joint is the most frequent degenerative disease of the jaw joint. Several clinical studies recommend the recourse to the viscosupplement because of its efficiency in the long term.
The present research has for objective to find clinical factors predictive of success or failure of viscosupplementation in ATM such as clinical severity before injection, the presence of a limited mouth opening or lenght of symptoms.
It is an open observational monocentrical prospective study. The recruitment is competitive and the study will be ended when 44 patients will have been included by taking into account a risk of trial exits or of lost of sight of 10 %.The main criterion is the influence of the radiological stage on the answer to the treatment.
Duration of inclusion 6 months. Duration of follow-up 6 months. Total duration of the study 12 months.
Detailed description
Forty patients presenting an ATM asserted by radiography and justifying a viscosupplement, without other selection criterion than the opinion of the investigator concerning the legitimacy of a viscosupplement and the agreement of the patient participating in the study.
The data collected during the consultations at J0, J90 and J180 will be inputed by the investigator in the paper version of the CRF.
The informations collected during the initial consultation (J0) are: demographic (sex, age, weight, size), pathological (history of the disease, target side, previous treatments, evaluation of pain at chewing and palpation (scale of Likert : 11 points), the inter-incisive distance during the maximal opening.
The informations collected during J90 and the final consultation (J180) are: the evaluation of pain at chewing and palpation (scale of Likert 11 points), the perception by the patient of the efficiency of the treatment (scale of Likert 4 points), patient satisfaction score, variation of its consumption of analgesic or of AINS (scale of Likert 5 points).
A descriptive analysis will be performed to characterize the demographic data, the history of the disease and its treatments, as well as the clinical and radiological data of the patients in the date of the inclusion.
The response to the treatment (Yes/No) will be estimated by 3 complementary terms, and for each one of them, the predictive response factors will be studied. Each patient will be classified in one of the treatment response categories based on the patients efficacy assessment, the pain decrease of at least 3 points or of at least 50% on the Likert scale, the satisfaction level of the patient.
The coefficients of the multivariate models (ANCOVA and mixed model) will be considered as significant if their p-value is inferior to the threshold of 5%.
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Forty patients having a hallux rigidus asserted radiologically and justifying according to the opinion of the rhumalologist or the surgeon a viscosupplementation. The study is realized in the conditions of daily practice, it modifies not at all the therapeutic care of the patient
Key inclusion criteria (4 listed)
- Patients of both genders, of all ages
- Hallux rigidus confirmed by radiography including frontal and side radiographies performed during the last 12 months
Key exclusion criteria (5 listed)
- Patient with hypersensitivity to hyaluronic acid or mannitol
- Patient with a contraindication to the injection procedure : infected skin lesions on or close to an injection site, infectious disease ongoing
- Patient who received a viscosuplement during the last 6 months
- Patient who received an intra-articular injection of corticoids in the target articulation during the last 3 month before the inclusion
- Patient not talking french
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
clinical factors associated with the treatment response in temporomandibular joint arthritis
Time frame: 6 months
Assessment of since how long the patient has these pains (in months)
2 secondary outcomes
clinical factors associated with the treatment response in temporomandibular joint arthritis
Time frame: 6 months
clinical factors associated with the treatment response in temporomandibular joint arthritis
Time frame: 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2018.
- Individual participant dataSharing planned: No
Related trials for Arthritis of Temporomandibular Joint
RecruitingObservational study
Dysphagia in Rheumatoid Arthritis
Rheumatoid Arthritis (RA
Enrolling by invitationPhase 2/3
Effectiveness of iPRF Injections in Temporomandibular Joints Degeneration Management
Temporomandibular Disorder, Temporomandibular Joint Disorders
Not yet recruitingObservational study
CBCT and Audiological Analysis of the TMJ-Tinnitus Relationship
Tinnitus, Temporomandibular Joint Disorders
Not yet recruitingObservational study
Clinical, Microbial and Tissue-based Characterization of Patients Treated for Severe Temporomandibular Joint Pathology
TMJ Disorder, Ankylosis
Recruiting
Exploring Radiotherapy of Temporomandibular Joint Arthritis
Arthritis of Temporomandibular Joint
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
DOMINIQUE BARON, MD principal investigator
CH LANNION
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Arthritis of Temporomandibular Joint and Temporomandibular Arthritis, run by Labrha at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
clinical factors associated with the treatment response in temporomandibular joint arthritis (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2018.